FY2023 · ended Dec 31, 2023 · Revenue $55,180, -58.4% YoY · Filed Mar 27, 2025
Gain Therapeutics, Inc (GANX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $13.1 million in cash and investments and $609,874 in total debt.
Revenue
$55,180
-58.4% vs prior year
Net income
$-20.16M
+1.2% vs prior year
Operating cash flow (TTM)
$-18.95M
-2.7% vs year-ago TTM
Free cash flow
$-18.90M
-0.1% vs prior year
EPS
$-0.61
+31.5% vs prior year
Dividend per share
None
Shares outstanding
42.24M
+52.0% vs prior year
Net cash
$12.47M
as of Jun 30, 2026
Operating margin
-40328.3%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1819411
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $55,180 | $132,640 | $133,928 |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M |
| Diluted EPS | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 |
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M |
| Free cash flow | — | -$18.9M | -$18.9M | -$14.8M | -$12.5M |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M |
| Stockholders' equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M |
| Cash and investments | $20.8M | $10.4M | $16.8M | $22.1M | $36.9M |
| Total debt | $732,067 | $653,015 | $1.0M | $1.3M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 28, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 28, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Jul 16, 2026 | Jul 16, 2026 |
All 240 Gain Therapeutics, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.